ASCO26: Jennifer Ligibel, MD, BWEL - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

Share

Objective:

To present updated results from the BWEL study regarding the impact of a weight loss intervention on patients with early breast cancer.

Approach:
  • Study Overview: The BWEL study focused on a weight loss intervention for patients with early breast cancer.
Key Findings:
  • The weight loss intervention led to significantly better physical function.
  • Participants reported improved global physical and mental health.
  • There was a reduction in symptoms among patients with early breast cancer.
Interpretation:

The findings suggest that weight loss interventions may have positive effects on health outcomes in early breast cancer patients.

Conclusion:

The BWEL study indicates that weight loss interventions can enhance physical and mental health in early breast cancer patients.

Original Source(s)

ASCO26: Jennifer Ligibel, MD, BWEL

  • July 1, 2026

Related Content

The Unrealized Potential of Cascade Testing

Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min